Last reviewed · How we verify

Growth hormone deficiency — Treatment Landscape & Competitive Intelligence

Growth hormone deficiency (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Growth hormone deficiency, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Ngenla somatrogon Pfizer Ireland Pharmaceuticals Growth hormone receptor 2023-01-01
Ngenla Somatrogon-Ghla Pfizer Ireland Pharmaceuticals Growth hormone receptor 2023-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Ireland Pharmaceuticals · 2 drugs in Growth hormone deficiency
  2. Pfizer Inc. · 1 drug in Growth hormone deficiency

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Growth hormone deficiency:

Cite this brief

Drug Landscape (2026). Growth hormone deficiency — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/growth-hormone-deficiency. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing